Please Wait
Applying Filters...
menu
    • menu
    Minakem delivers API, HPAPI, steroids & CDMO services for generics with FDA/GMP certification, regulatory know-how & proven success.

    Virtual Booth

    Contact Supplier

    Boai NKY Pharmaceuticals Ltd. is one of the largest global PVP suppliers.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-04-20

    Virtual Booth

    An Enquiry

    Nanjing Well is focused on R&D, production & sales of Pharmaceutical Excipients & Synthetic Lubricating base oils.

    Virtual Booth

    Contact Supplier

    Ever Pharma, highly specialized CDMO in producing complex injectables including high potency & controlled substances, suspensions, etc.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2026-04-20

    Virtual Booth

    An Enquiry

    Menu

    Ofirnoflast

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Halia Presents Ofirnoflast Phase 2 Data in Lower-Risk MDS at EHA
    Halia Presents Ofirnoflast Phase 2 Data in Lower-Risk MDS at EHA

    12 May 2026

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/halia-therapeutics-to-present-final-phase-2-ofirnoflast-data-in-lower-risk-mds-at-eha2026-and-announces-appointment-of-han-myint-md-facp-as-chief-medical-officer-302769531.html

    PR NEWSWIRE
    12 May 2026
    Share Share
    Halia Therapeutics Reports Ofirnoflast Success In Lower-Risk MDS
    Halia Therapeutics Reports Ofirnoflast Success In Lower-Risk MDS

    08 Dec 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/halia-therapeutics-announces-positive-phase-2a-data-for-ofirnoflast-in-lower-risk-mds-at-ash-2025-302635415.html

    PR NEWSWIRE
    08 Dec 2025
    Share Share
    Halia Therapeutics Unveils Novel NEK7 Inhibitor Data At ASH 2025
    Halia Therapeutics Unveils Novel NEK7 Inhibitor Data At ASH 2025

    10 Nov 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/halia-therapeutics-to-present-groundbreaking-data-on-novel-allosteric-nek7-inhibitor-ofirnoflast-at-the-2025-american-society-of-hematology-annual-meeting-302609730.html

    PR NEWSWIRE
    10 Nov 2025
    Share Share
    Ofirnoflast Gets Orphan Drug Tag for Myelodysplastic Syndromes
    Ofirnoflast Gets Orphan Drug Tag for Myelodysplastic Syndromes

    23 Oct 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/ofirnoflast-ht-6184-receives-orphan-drug-designation-from-us-fda-for-myelodysplastic-syndromes-302592239.html

    PR NEWSWIRE
    23 Oct 2025
    Share Share
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.